Previous 10 | Next 10 |
VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today ann...
Multi-Year, Multi-Million Dollar Phase 2 Award for Development of High Frequency 2-18 GHz XBAW ® Filter Technology Award Invests in Development of Akoustis’ Single-Crystal and XP3F Filter Technologies New Materials and Device Manufacturing to Target Commercial...
Charlotte, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, an...
Q1 Revenue Up 26% Year-Over-Year, In-Line with Prior Guidance Guiding Revenue Flat in December Quarter, then 18 to 25% Growth with Record Revenue Projected in March Quarter Growth, Cost Savings Initiatives, Chips ITC Refund Support Operating Cash Flow Breakeven <1 Year Away ...
New Designs Developed Using Akoustis’ Proprietary XBAW Foundry Process Customer Designed Filters to Target Wi-Fi 7 AP and China Mobile Markets Production Ramp Expected in First Half Calendar 2024 Charlotte, N.C., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologi...
VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, tod...
VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today ann...
VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its...
Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed $40 million funded at close; $50 million of additional non-dilutive capital available at the Company’s option, based on the achievement of certain revenue thresholds Capita...
ONERHT Foundation Charity Golf 2023 raises more than S$400,000 for disadvantaged groups SINGAPORE, Oct 9, 2023 - (ACN Newswire) - ONERHT Foundation Ltd ("Foundation"), the corporate social responsibility arm of RHTLaw Asia LLP and the RHT Group of Companies (collectively, "ONERHT"),...
News, Short Squeeze, Breakout and More Instantly...
Avianca Holdings S.A. American Depositary Shares (Each representing 8 preferred Shares) Company Name:
AVH Stock Symbol:
NYSE Market:
VALENCIA, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has ...
Charlotte, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (Nasdaq: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applica...
Charlotte, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, has...